Drug Profile
Research programme: calcium channel stabilisers - ARMGO Pharma
Alternative Names: Ryanodine receptor calcium-release channel (RyR) modulators - ARMGO Pharma; Rycals; S 107Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator ARMGO Pharma
- Class Antidementias; Antiparkinsonians; Antipsychotics; Small molecules
- Mechanism of Action Ryanodine receptor calcium release channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Cognition disorders; Diabetes mellitus; Huntington's disease; Musculoskeletal disorders; Post-traumatic stress disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Alzheimer's-disease in USA (PO)
- 28 Sep 2021 No recent reports of development identified for research development in Diabetes-mellitus in USA (PO)
- 28 Sep 2021 No recent reports of development identified for research development in Huntington's-disease in USA (PO)